article · Bulletin of the World Health Organization
This study evaluates the financial and economic costs alongside the cost-effectiveness of thermal ablation compared with cryotherapy and loop diathermy in Zambia. Evaluating outcomes within a randomised controlled trial involving 3,124 women eligible for ablative treatment, the analysis tracked programme, personnel, equipment, and consumable expenses. In trial conditions, thermal ablation proved less costly than cryotherapy and loop diathermy per woman treated and per woman completing follow-up. When modelling the integration of treatment into routine cervical cancer services, thermal ablation maintained lower costs, driven mainly by reduced personnel expenses. Decision-tree modelling demonstrated that thermal ablation is a cost-effective alternative to both cryotherapy and loop diathermy, offering an economically viable option for cervical cancer screen-and-treat programmes.
Cervical cancer programmes require interventions that are both clinically effective and affordable to scale. By demonstrating that thermal ablation offers lower delivery and personnel costs compared to established methods like cryotherapy and loop diathermy, these findings help health systems allocate constrained budgets more efficiently when expanding screening and treatment services.
The findings are directly applicable to health service planners, procurement bodies, and public health programmes implementing cervical cancer screen-and-treat protocols. Because the intervention was assessed within a randomised controlled trial and modelled for routine healthcare delivery, thermal ablation represents a near-market, tested technology ready for operational integration and wider health service adoption.
AI-generated from the published abstract. Always read the original work before citing.
Objective: To estimate the financial and economic costs and the cost-effectiveness of thermal ablation compared to cryotherapy and loop diathermy within a screen-and-treat approach to cervical cancer screening in Zambia. Methods: We analysed costs within a randomized controlled trial in which women eligible for ablative treatment after cervical cancer screening were assigned to one of three treatment arms: thermal ablation, cryotherapy or loop diathermy. We used a microcosting approach to calculate programme, personnel, equipment and consumable costs for two groups: women treated without follow-up (screened-and-treated) and women who completed follow-up (follow-up-completed). We also estimated trial costs and projected costs if the screen-and-treat approach were to be integrated into routine cervical cancer services. To assess how cost-effective the treatments were, we used a decision tree model. Findings: Out of the 3124 women who were screened-and-treated, 2386 (76.4%) completed follow-up. In the trial scenario, costs for thermal ablation were lower than cryotherapy and loop diathermy, both per screened-and-treated woman (39.6 United States dollars (US$) versus US$ 42.3 and US$ 50.6, respectively) and per follow-up-completed woman (US$ 55.1 versus US$ 57.9 and US$ 66.2, respectively). In the routine scenario, costs for thermal ablation were also lower than for other treatments (US$ 12.7 versus US$ 15.6 and US$ 34.9, respectively, for screen-and-treat) due to significantly lower personnel costs. Thermal ablation was cost-effective compared to cryotherapy and loop diathermy. Conclusion: Our study suggests that thermal ablation is a cost-effective option for the screen-and-treat approach to cervical cancer screening compared with cryotherapy and loop diathermy.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2471/blt.24.292792
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.